GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evofem Biosciences Inc (OTCPK:EVFM) » Definitions » Cyclically Adjusted PB Ratio

Evofem Biosciences (Evofem Biosciences) Cyclically Adjusted PB Ratio : 0.00 (As of May. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Evofem Biosciences Cyclically Adjusted PB Ratio?

As of today (2024-05-28), Evofem Biosciences's current share price is $0.0159. Evofem Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $1,085.70. Evofem Biosciences's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Evofem Biosciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

EVFM's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.73
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Evofem Biosciences's adjusted book value per share data for the three months ended in Mar. 2024 was $-1.451. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1,085.70 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Evofem Biosciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Evofem Biosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evofem Biosciences Cyclically Adjusted PB Ratio Chart

Evofem Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Evofem Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Evofem Biosciences's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Evofem Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evofem Biosciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's Cyclically Adjusted PB Ratio falls into.



Evofem Biosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Evofem Biosciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.0159/1085.7
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Evofem Biosciences's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.451/131.7762*131.7762
=-1.451

Current CPI (Mar. 2024) = 131.7762.

Evofem Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 8,918.644 100.428 11,702.586
201412 53,481.148 99.070 71,137.214
201503 48,068.852 99.621 63,584.227
201506 40,643.443 100.684 53,194.587
201509 26,829.508 100.392 35,217.031
201512 19,513.934 99.792 25,768.216
201603 15,044.715 100.470 19,732.532
201606 13,039.837 101.688 16,898.144
201609 11,198.374 101.861 14,487.185
201612 9,686.992 101.863 12,531.722
201703 7,345.528 102.862 9,410.316
201706 5,295.122 103.349 6,751.593
201709 3,943.089 104.136 4,989.699
201712 -235,403.252 104.011 -298,242.649
201803 -1,931.573 105.290 -2,417.481
201806 391.220 106.317 484.904
201809 -729.348 106.507 -902.391
201812 -1,692.464 105.998 -2,104.065
201903 -1,884.455 107.251 -2,315.386
201906 1,445.557 108.070 1,762.662
201909 964.543 108.329 1,173.309
201912 609.116 108.420 740.333
202003 38.557 108.902 46.656
202006 1,580.696 108.767 1,915.080
202009 927.566 109.815 1,113.065
202012 31.044 109.897 37.225
202103 -255.059 111.754 -300.755
202106 108.339 114.631 124.543
202109 -710.643 115.734 -809.145
202112 -1,203.588 117.630 -1,348.337
202203 -1,299.452 121.301 -1,411.669
202206 -341.516 125.017 -359.981
202209 -95.643 125.227 -100.645
202212 -72.909 125.222 -76.725
202303 -32.645 127.348 -33.780
202306 -22.052 128.729 -22.574
202309 -9.922 129.860 -10.068
202312 -3.324 129.419 -3.385
202403 -1.451 131.776 -1.451

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evofem Biosciences  (OTCPK:EVFM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Evofem Biosciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Evofem Biosciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evofem Biosciences (Evofem Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Executives
Yan Zhang officer: Chief Financial Officer 6166 TIKI CT, SAN DIEGO CA 92130
Kim P. Kamdar director, 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Jenny C. Yip director 12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130
Atkinson Katherine Cocca officer: Chief Commercial Officer 12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130
Saundra L Pelletier director, officer: Chief Executive Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Alexander A Fitzpatrick officer: General Counsel and Secretary 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Justin J. File officer: Chief Financial Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Anthony Stephen O'brien director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Russell Barrans officer: Chief Commercial Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Dale Rarick director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130
William Walmsley Hall director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130
Invesco Ltd. 10 percent owner 1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309
Link Fund Solutions Ltd 10 percent owner 65 GRESHAM STREET, LONDON X0 EC2V 7NQ
Acacia Research Corp 10 percent owner 767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017
Kelly Culwell officer: Chief Medical Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130